tiprankstipranks
Carmell Therapeutics (CTCX)
NASDAQ:CTCX
US Market

Carmell Therapeutics (CTCX) Income Statement

Compare
61 Followers

Carmell Therapeutics Income Statement

Last quarter (Q3 2024), Carmell Therapeutics's total revenue was $20.52K, a decrease of -99.45% from the same quarter last year. In Q3, Carmell Therapeutics's net income was $-2.88M. See Carmell Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00
Gross Profit
$ -124.79K$ -242.56K$ 0.00
Operating Expenses
$ 5.09M$ 5.51M$ 1.94M
Depreciation and Amortization
$ 124.79K$ 242.56K$ 242.12K
EBITDA
$ -15.19M$ -5.25M$ -1.66M
Operating Income
$ -5.22M$ -5.51M$ -1.94M
Other Income/Expenses
$ -10.99M$ -3.54M$ -4.54M
Pretax Income
$ -16.21M$ -9.05M$ -6.48M
Net Income
$ -15.45M$ -9.05M$ -6.48M
Per Share Metrics
$ ―$ ―$ ―
Basic EPS
$ -1.46$ -0.46$ -0.33
Diluted EPS
$ -1.46$ -0.46$ -0.33
Weighted Average Shares Outstanding
11.02M 19.77M 19.77M
Weighted Average Shares Outstanding (Diluted)
11.02M 19.77M 19.77M
Currency in USD

Carmell Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis